News | April 05, 2023
Israeli researchers develop an effective drug to prevent muscle diseases
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Subscribe To Our Newsletter & Stay Updated
